Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
291.6 INR | +0.71% | +9.15% | +16.82% |
Apr. 18 | India's Biocon developing its own version of Wegovy, clinical trial likely next year | RE |
Apr. 18 | Biocon Signs Licensing and Supply Pact with Biomm to Commercialize Generic Ozempic in Brazil | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+16.82% | 4.15B | |
-3.28% | 104B | |
-0.06% | 97.42B | |
+1.31% | 22.2B | |
-18.25% | 21.23B | |
-10.74% | 18.33B | |
-42.83% | 16.35B | |
-17.17% | 15.06B | |
+3.60% | 13.98B | |
+27.51% | 11.66B |
- Stock Market
- Equities
- BIOCON Stock
- News Biocon Limited
- Biocon Biologics Launches Insulin Glargine Injections in US